Aarti Drugs Limited AARTIDRUGS NSEPHARMA

Q: What is the current share price of Aarti Drugs Limited (AARTIDRUGS)?

As of 2026-10-23 04:58 IST, Aarti Drugs Limited (AARTIDRUGS) trades at ₹388.60 on NSE. Its 52-week range is ₹319.75 to ₹522.55.

Q: What is the market capitalisation of AARTIDRUGS?

Aarti Drugs Limited (AARTIDRUGS) has a market capitalisation of ₹3,546.75 Cr on NSE.

Q: What is the P/E ratio of AARTIDRUGS?

AARTIDRUGS trades at a trailing price-to-earnings (P/E) ratio of 18.57. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 2.43.

Q: Does AARTIDRUGS pay a dividend?

Aarti Drugs Limited (AARTIDRUGS) currently offers a dividend yield of 0.48%.

Q: What is the return on equity (ROE) of AARTIDRUGS?

AARTIDRUGS has a return on equity (ROE) of 12.58%. Its return on capital employed (ROCE) is 12.92%.

Q: Is AARTIDRUGS a good stock to buy?

This page provides a data-driven analysis of Aarti Drugs Limited (AARTIDRUGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.aartidrugs.co.in

Company Profile ↓

₹388.60

-20.18% 1Y

Mkt Cap₹3,546.75 Cr

P/E18.57

P/B2.43

Div. Yield0.48%

52W High₹522.55

52W Low₹319.75

Book Value₹169.79

EPS (TTM)₹20.93

Company Overview

Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 18.6, below the sector median of 36.4.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.37.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹2,565.31 Cr (+7.5% YoY); net profit ₹194.92 Cr.
Trailing 12 Months Year-on-year growth — revenue +19.0%, earnings -6.9%.
5-Year Trend Long-term compounding — revenue CAGR -1.8%, profit CAGR 5.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-1.76%
1 Year:	19.00%

Compounded Profit Growth

5 Years:	5.43%
1 Year:	-6.90%

Stock Price Performance

1 Year:	-20.18%
6 Months:	+1.78%
3 Months:	-5.22%
1 Month:	-10.77%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 34% of range

₹319.75 ₹522.55

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)31.29 · Neutral

Price Performance

1M-10.77%

3M-5.22%

6M+1.78%

1Y-20.18%

Valuation vs Sector

P/E of 18.57 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -1.8% CAGR over 5 years.
Trading 25.6% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

18.57

Industry PE

36.43

Forward P/E

13.93

PEG Ratio

Book Value

₹169.79

Price to Book

2.43

P/S

1.41

EV/EBITDA

12.89

Dividend Yield

0.48%

Growth (CAGR)

Revenue 5Y

-1.76%

Profit 5Y

5.43%

Revenue (YoY)

19.00%

Earnings (YoY)

-6.90%

Profitability & Returns

ROCE

12.92%

ROE

12.58%

ROA

6.92%

Profit Margin

7.14%

Op Margin

11.46%

Gross Margin

37.52%

EPS (Latest Qtr)

₹5.49

EPS (TTM)

₹20.93

Balance Sheet & Liquidity

Debt/Equity

0.37

Quick Ratio

1.06

Current Ratio

1.59

Debt

₹576.64 Cr

Total Assets

₹2,815.26 Cr

Current Assets

₹1,467.77 Cr

Working Capital

₹545.51 Cr

Ownership

Promoter Holding

59.56%

Chg in Prom Hold

-0.60%

FII / Inst Holding

11.07%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

₹3,546.75 Cr

Total Revenue (TTM)

₹2,677.58 Cr

EBITDA

₹335.95 Cr

Free Cash Flow

₹80.22 Cr

Operating Cash Flow

₹253.54 Cr

Shares Outstanding

₹9.13 Cr

Gross Margin

37.52%

Payout Ratio

9.55%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AARTIDRUGS Aarti Drugs Limited NSEPHARMA	388.60	18.57	₹3,546.75 Cr	0.48%	12.92%	12.58%	-1.76%	5.43%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,745.10	34.62	₹4.19 L Cr	0.91%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	9,190.00	83.58	₹2.44 L Cr	0.32%	18.96%	15.32%	10.98%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,553.80	72.74	₹1.73 L Cr	0.81%	9.05%	25.79%	13.27%	20.22%
5	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,117.30	24.90	₹1.11 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
6	LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA	631.35	164.41	₹1.09 L Cr	0.00%	7.21%	5.65%	35.38%	66.99%
7	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	7,600.00	52.32	₹1.09 L Cr	0.25%	19.20%	20.48%	14.85%	33.34%
8	LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA	2,012.50	99.48	₹1.09 L Cr	0.12%	19.53%	16.77%	3.77%	4.00%
9	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,314.00	31.51	₹1.06 L Cr	0.99%	14.86%	11.27%	7.23%	11.45%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	742.00 Cr	661.00 Cr	642.00 Cr	606.00 Cr	620.00 Cr	555.00 Cr	598.00 Cr	557.00 Cr	676.76 Cr	590.51 Cr	652.79 Cr	601.71 Cr	720.30 Cr	702.78 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	435.55 Cr	373.39 Cr	408.29 Cr	386.64 Cr	450.42 Cr	427.60 Cr
Gross Profit	-	-	-	-	-	-	-	-	241.21 Cr	217.12 Cr	244.50 Cr	215.07 Cr	269.88 Cr	275.18 Cr
Operating Expenses	649.00 Cr	577.00 Cr	565.00 Cr	536.00 Cr	534.00 Cr	490.00 Cr	531.00 Cr	495.00 Cr	162.78 Cr	157.76 Cr	176.47 Cr	177.98 Cr	192.12 Cr	195.44 Cr
Operating Income	82.00 Cr	71.00 Cr	63.00 Cr	57.00 Cr	72.00 Cr	52.00 Cr	53.00 Cr	48.00 Cr	78.43 Cr	59.36 Cr	68.03 Cr	37.09 Cr	77.76 Cr	79.74 Cr
EBITDA	94.00 Cr	84.00 Cr	76.00 Cr	70.00 Cr	86.00 Cr	65.00 Cr	67.00 Cr	62.00 Cr	95.19 Cr	74.39 Cr	84.37 Cr	56.26 Cr	96.56 Cr	96.92 Cr
Interest Expense	9.00 Cr	9.00 Cr	8.00 Cr	8.00 Cr	9.00 Cr	9.00 Cr	9.00 Cr	9.00 Cr	9.16 Cr	8.56 Cr	7.70 Cr	9.29 Cr	8.16 Cr	9.22 Cr
Pretax Income	73.00 Cr	64.00 Cr	56.00 Cr	52.00 Cr	64.00 Cr	44.00 Cr	46.00 Cr	51.00 Cr	71.15 Cr	51.11 Cr	60.41 Cr	29.02 Cr	70.36 Cr	69.24 Cr
Tax Provision	16.79 Cr	15.36 Cr	16.80 Cr	15.08 Cr	16.64 Cr	10.56 Cr	11.04 Cr	13.77 Cr	8.38 Cr	-2.86 Cr	15.25 Cr	-11.53 Cr	15.10 Cr	19.11 Cr
Net Income	56.00 Cr	48.00 Cr	40.00 Cr	37.00 Cr	47.00 Cr	33.00 Cr	35.00 Cr	37.00 Cr	62.86 Cr	53.91 Cr	45.28 Cr	40.54 Cr	55.19 Cr	50.17 Cr
Diluted EPS	6.06	5.17	4.31	3.99	5.15	3.62	3.84	4.06	6.88	5.91	4.95	4.44	6.05	5.49

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	1,097.00 Cr	1,140.00 Cr	1,195.00 Cr	1,244.00 Cr	1,561.00 Cr	1,806.00 Cr	2,155.00 Cr	-	2,705.57 Cr	2,508.87 Cr	2,387.03 Cr	2,565.31 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	2,222.60 Cr	2,024.01 Cr	1,542.10 Cr	1,618.72 Cr
Gross Profit	-	-	-	-	-	-	-	-	482.97 Cr	484.87 Cr	844.93 Cr	946.59 Cr
Operating Expenses	925.00 Cr	960.00 Cr	1,005.00 Cr	1,042.00 Cr	1,350.00 Cr	1,541.00 Cr	1,714.00 Cr	-	216.62 Cr	207.16 Cr	613.65 Cr	704.36 Cr
Operating Income	141.00 Cr	143.00 Cr	152.00 Cr	162.00 Cr	168.00 Cr	217.00 Cr	390.00 Cr	-	266.35 Cr	277.70 Cr	231.28 Cr	242.23 Cr
EBITDA	172.00 Cr	180.00 Cr	190.00 Cr	202.00 Cr	211.00 Cr	266.00 Cr	440.00 Cr	-	307.80 Cr	320.49 Cr	303.42 Cr	311.58 Cr
Interest Expense	42.00 Cr	48.00 Cr	40.00 Cr	38.00 Cr	44.00 Cr	37.00 Cr	26.00 Cr	-	33.29 Cr	33.52 Cr	35.87 Cr	33.71 Cr
Pretax Income	100.00 Cr	95.00 Cr	116.00 Cr	125.00 Cr	131.00 Cr	185.00 Cr	369.00 Cr	-	224.18 Cr	235.53 Cr	211.77 Cr	210.90 Cr
Tax Provision	23.00 Cr	26.60 Cr	33.64 Cr	42.50 Cr	41.92 Cr	44.40 Cr	88.56 Cr	-	57.82 Cr	63.94 Cr	43.67 Cr	15.96 Cr
Net Income	77.00 Cr	69.00 Cr	82.00 Cr	82.00 Cr	90.00 Cr	141.00 Cr	280.00 Cr	-	166.31 Cr	171.42 Cr	168.16 Cr	194.92 Cr
Diluted EPS	7.97	7.09	8.57	8.73	9.52	15.17	30.09	-	17.97	18.56	18.35	21.36

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	1,004.00 Cr	1,102.00 Cr	1,191.00 Cr	1,389.00 Cr	1,455.00 Cr	1,576.00 Cr	1,766.00 Cr	-	2,421.40 Cr	2,432.36 Cr	2,574.68 Cr	2,815.26 Cr
Current Assets	-	-	-	-	-	-	-	-	1,491.79 Cr	1,320.72 Cr	1,338.36 Cr	1,467.77 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	7.50 Cr	6.74 Cr	4.58 Cr	7.27 Cr
Inventory	-	-	-	-	-	-	-	-	516.29 Cr	485.89 Cr	472.93 Cr	490.78 Cr
Receivables	-	-	-	-	-	-	-	-	864.84 Cr	704.55 Cr	751.18 Cr	829.87 Cr
Total Liabilities	-	-	-	-	-	-	-	-	1,228.73 Cr	1,150.40 Cr	1,205.34 Cr	1,266.04 Cr
Current Liabilities	-	-	-	-	-	-	-	-	949.48 Cr	795.54 Cr	836.97 Cr	922.26 Cr
Long Term Debt	-	-	-	-	-	-	-	-	204.68 Cr	275.33 Cr	284.00 Cr	256.87 Cr
Total Debt	448.00 Cr	483.00 Cr	480.00 Cr	546.00 Cr	507.00 Cr	389.00 Cr	351.00 Cr	-	608.91 Cr	564.28 Cr	615.07 Cr	576.64 Cr
Total Equity	308.00 Cr	357.00 Cr	400.00 Cr	456.00 Cr	544.00 Cr	652.00 Cr	913.00 Cr	-	1,192.43 Cr	1,281.55 Cr	1,369.00 Cr	1,548.86 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	9.26 Cr	9.19 Cr	9.13 Cr	9.13 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	105.00 Cr	133.00 Cr	175.00 Cr	70.00 Cr	143.00 Cr	251.00 Cr	155.00 Cr	-	133.32 Cr	358.92 Cr	244.58 Cr	253.54 Cr
Investing Cash Flow	-107.00 Cr	-99.00 Cr	-107.00 Cr	-74.00 Cr	-62.00 Cr	-33.00 Cr	-72.00 Cr	-	-163.97 Cr	-223.65 Cr	-164.63 Cr	-173.41 Cr
Financing Cash Flow	1.00 Cr	-33.00 Cr	-68.00 Cr	4.00 Cr	-80.00 Cr	-215.00 Cr	-81.00 Cr	-	16.54 Cr	-136.03 Cr	-82.12 Cr	-77.44 Cr
Capital Expenditure	-107.00 Cr	-99.00 Cr	-107.00 Cr	-75.00 Cr	-63.00 Cr	-37.00 Cr	-77.00 Cr	-	-164.82 Cr	-226.33 Cr	-177.16 Cr	-173.32 Cr
Free Cash Flow	-2.00 Cr	34.00 Cr	68.00 Cr	-5.00 Cr	80.00 Cr	214.00 Cr	78.00 Cr	-	-31.50 Cr	132.59 Cr	67.42 Cr	80.22 Cr
Net Change in Cash	-1.00 Cr	1.00 Cr	-0	0	1.00 Cr	2.00 Cr	2.00 Cr	-	-14.11 Cr	-76.07 L	-2.17 Cr	2.69 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	17.9%	19.3%	35.4%	36.9%
Operating Margin %	12.9%	12.5%	12.7%	13.0%	10.8%	12.0%	18.1%	-	9.8%	11.1%	9.7%	9.4%
Net Margin %	7.0%	6.1%	6.9%	6.6%	5.8%	7.8%	13.0%	-	6.1%	6.8%	7.0%	7.6%
ROE %	25.0%	19.3%	20.5%	18.0%	16.5%	21.6%	30.7%	-	13.9%	13.4%	12.3%	12.6%
ROCE %	-	-	-	-	-	-	-	-	18.1%	17.0%	13.3%	12.8%

Shareholding Pattern

Insiders

59.56%

Institutions

11.07%

Public Float

27.39%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AARTIDRUGS

Google News Wed, 20 May 2026

Aarti Drugs Limited Just Recorded A 6.8% EPS Beat: Here's What Analysts Are Forecasting Next - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQQ1kyZ3ZnS01jd0x3T0NNdXpxbmhJRW9CaHlIdlUzT2NaSjJIb3hWempSaW8yNGFmWGcxYWFZcllhWVBHUG1ESExrUTFwZXdKcGw0VG45RHVFY3FiUFNCTE02VXhrZWpsZE81Nnd6RFVjR1BqYncwRUpHd1BzOFZ5UXdXdGplS0Vyd0ZueT…

Google News Fri, 31 Jul 2026

Aarti Drugs Q1 profit falls 7% despite 19% revenue growth; announces leadership transition - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQNVQwaEVHdWZCZmtoWlNTSmxpUjhMZW9CVHVUSkgwUFdfNzNnYXVhR0UzeWtaV1BmUFZjZXdjdkRENV9aekd3Y1lGN1UwMDJWbGtwS0txZmswZzk1QUZ0ZU5TNVNMNVlyaDNpbS1qaFZ4aFZTMUxFVmRic2ZRd1gwNXMtZHdPa05vOGNQa2…

Google News hu, 27 Aug 2026

Aarti Drugs approves 8 lakh performance stock option grants - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPVkdYRzgyNXdtM2p4YUtCMlk5dUE1U2RhNEVGcFhaM1hjVC15N1dZN1dMMGF0bURfelhEUnNjNEdSYmttaFp4c2hTbWdzbEZLSm1uVHpOdzh4andHb3B5SUdnNGJYR3AzWkxvTFRNNUFabEtOYkxmUGNfRHRyVTNjbjRja2JzTjhHRUZiaW…

Google News Mon, 21 Sep 2026

Aarti Drugs Limited (AARTIDRUGS.NS) Edges Higher: Shares Trade Near ₹435.50 as Pharma Watches Key Levels - Death Cross - siam.in

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNUzBRRGRPdGxJLWFzQ21VQVBacHY1RVcxYnlESVB4SVo3NEFDUzhDelNjMm1BUDFKQWlrVm52a1B0VFltaGZNdG80ZkdrRGw2eE9zUFFHeTFSRHRlcU9FRHhWV1BjUVdiWlhRbW1kYklnWWJGbURxZXdhNWFoZG9RR2VybDhmeklwU25XQ1…

Google News Wed, 13 May 2026

Why Is Aarti Drugs Share Price Falling: Key Reasons and Investor Analysis 2026 - Univest

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBVT1FvRzBRUnFKMDlMelFhR1hqZlVKTnVYNVBtSmFaOUFDSXZldTFudmQxd3VrNW5mOFp3UnJQd0YtLTVLZE9CVjAzNVZjLXhQYndSTGdQV0pJZUZPeENpWlY3UkI4cHVHNXBCZzZRM1g?oc=5" target="_blank">Why Is Aarti Dru…

Google News hu, 27 Aug 2026

Aarti Drugs PSOP 2026 Board Approval: Key Details - Kalkine India

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbnItTUFMb3ZHMWZuaHJWM2dXcF9GT3YwbWNqemZHb0l6c2dOZG5ZU2VRN0FldGRTbmgyZURfMmcxWXlDSlZGUFBNV2ZITzQxOFRJcDRrSjMycUpyQUw1M2xVRHJlQkZQS2dLYWdvak9xdEpvcXRXMTNnbWItOGFSNWhoRURwVU5ZSmNvaU…

AARTIDRUGS — Frequently Asked Questions

What is the current share price of Aarti Drugs Limited (AARTIDRUGS)?

As of 2026-10-23 04:58 IST, Aarti Drugs Limited (AARTIDRUGS) trades at ₹388.60 on NSE. Its 52-week range is ₹319.75 to ₹522.55.

What is the market capitalisation of AARTIDRUGS?

Aarti Drugs Limited (AARTIDRUGS) has a market capitalisation of ₹3,546.75 Cr on NSE.

What is the P/E ratio of AARTIDRUGS?

AARTIDRUGS trades at a trailing price-to-earnings (P/E) ratio of 18.57. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 2.43.

Does AARTIDRUGS pay a dividend?

Aarti Drugs Limited (AARTIDRUGS) currently offers a dividend yield of 0.48%.

What is the return on equity (ROE) of AARTIDRUGS?

AARTIDRUGS has a return on equity (ROE) of 12.58%. Its return on capital employed (ROCE) is 12.92%.

Is AARTIDRUGS a good stock to buy?

This page provides a data-driven analysis of Aarti Drugs Limited (AARTIDRUGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

Aarti Drugs Limited AARTIDRUGS NSEPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

Aarti Drugs Limited Just Recorded A 6.8% EPS Beat: Here's What Analysts Are Forecasting Next - Simply Wall Street

Aarti Drugs Q1 profit falls 7% despite 19% revenue growth; announces leadership transition - CNBC TV18

Aarti Drugs approves 8 lakh performance stock option grants - scanx.trade

Aarti Drugs Limited (AARTIDRUGS.NS) Edges Higher: Shares Trade Near ₹435.50 as Pharma Watches Key Levels - Death Cross - siam.in

Why Is Aarti Drugs Share Price Falling: Key Reasons and Investor Analysis 2026 - Univest

Aarti Drugs PSOP 2026 Board Approval: Key Details - Kalkine India

AARTIDRUGS — Frequently Asked Questions

What is the current share price of Aarti Drugs Limited (AARTIDRUGS)?

What is the market capitalisation of AARTIDRUGS?

What is the P/E ratio of AARTIDRUGS?

Does AARTIDRUGS pay a dividend?

What is the return on equity (ROE) of AARTIDRUGS?

Is AARTIDRUGS a good stock to buy?

Explore More